Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 0.54 |
| ▸ | CNR1 | P21554 | 15/20 | 0.54 |
| ▸ | FAAH | O00519 | 5/20 | 0.49 |
| ▸ | ABHD12 | Q8N2K0 | 3/20 | 0.47 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4123420 | 0.77 | PDE4A (0.44) | — | |
| SCHEMBL4137219 | 0.74 | ADORA1 (0.45) | — | |
| SCHEMBL5527487 | 0.69 | CNR2 (0.60) | CNR2CNR1FAAHABHD12 | |
| SCHEMBL5527500 | 0.69 | CNR2 (0.65) | CNR2CNR1FAAH | |
| SCHEMBL24002947 | 0.69 | CNR2 (0.84) | CNR2CNR1 | |
| SCHEMBL3853836 | 0.67 | EGLN3 (0.66) | CNR2CNR1 | |
| SCHEMBL4143701 | 0.67 | ADORA1 (0.46) | — | |
| SCHEMBL5534556 | 0.67 | CNR2 (0.58) | CNR2CNR1FAAHABHD12ABHD6 | |
| SCHEMBL24002806 | 0.67 | CNR2 (0.79) | CNR2CNR1FAAHABHD12 | |
| SCHEMBL5527459 | 0.65 | CNR2 (0.52) | CNR2CNR1FAAHABHD12ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090060867-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090060867-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090060867-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090060867-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI | POLR2E, POLR2H, POLI | CNR2 3837/4885CNR1 3302/4885FAAH 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.